

**This Page Is Inserted by IFW Operations
and is not a part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- **BLACK BORDERS**
- **TEXT CUT OFF AT TOP, BOTTOM OR SIDES**
- **FADED TEXT**
- **ILLEGIBLE TEXT**
- **SKEWED/SLANTED IMAGES**
- **COLORED PHOTOS**
- **BLACK OR VERY BLACK AND WHITE DARK PHOTOS**
- **GRAY SCALE DOCUMENTS**

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 48/00	A1	(11) International Publication Number: WO 93/03770 (43) International Publication Date: 4 March 1993 (04.03.93)
(21) International Application Number: PCT/US92/07133 (22) International Filing Date: 24 August 1992 (24.08.92) (30) Priority data: 748,997 23 August 1991 (23.08.91) US (71) Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA [US/US]; Regents Hall, Lincoln, NB 68583-0745 (US). (72) Inventor: SMITH, Larry, J. ; 3316 South 54th Street, Omaha, NB 68106 (US). (74) Agent: FLOYD, John, P.; P.O. Box 3609, Williamsburg, VA 23187-3609 (US).		(81) Designated States: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: METHOD AND COMPOSITIONS FOR CELLULAR REPROGRAMMING (57) Abstract The present invention provides methods and compositions useful in treating certain diseases herein termed "Aberrant Programming Diseases", including cancer and AIDS. According to one aspect of the invention, there is provided a method for treating an individual having an Aberrant Programming Disease comprising administering to said individual an effective amount of a composition selected from the group consisting of an expression vector, a double stranded oligodeoxynucleotide, and an antisense oligodeoxynucleotide; said composition capable of regulating expression of a transcriptional regulator, said transcriptional regulator being expressed by the Aberrant Programming cells and further characterized by exhibiting a therapeutically useful change in said cell behavior in the Reprogramming Test. In a separate embodiment new antisense oligodeoxynucleotides are provided.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	MN	Mongolia
AU	Australia	FR	France	MR	Mauritania
BB	Barbados	GA	Gabon	MW	Malawi
BE	Belgium	GB	United Kingdom	NL	Netherlands
BF	Burkina Faso	GN	Guinea	NO	Norway
BG	Bulgaria	GR	Greece	NZ	New Zealand
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	PT	Portugal
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	RU	Russian Federation
CG	Congo	KP	Democratic People's Republic of Korea	SD	Sudan
CH	Switzerland	KR	Republic of Korea	SE	Sweden
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovak Republic
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CS	Czechoslovakia	LU	Luxembourg	SU	Soviet Union
CZ	Czech Republic	MC	Monaco	TD	Chad
DE	Germany	MG	Madagascar	TG	Togo
DK	Denmark	MI	Mali	UA	Ukraine
ES	Spain			US	United States of America

METHOD AND COMPOSITIONS FOR CELLULAR REPROGRAMMING

BACKGROUND OF THE INVENTION

Field of the Invention

5 The present invention relates to methods and compositions useful in treating disorders in which the direct cause of the clinical disorder is the expression in the primary diseased cells of a differentiation program that does not normally exist. Such disorders are hereinafter referred to as Aberrant Programming (AP) Diseases. The invention also relates to method and compositions useful in therapeutically reprogramming normal cells.

15 As will be discussed more fully hereinafter, the AP diseases of this invention constitute a new disease classification and there is presented a novel molecular model of pathogenesis for these diseases. According to the molecular model of this invention, the basic disease causing entity in the AP diseases is a specific type of relational alteration among certain cellular components involved in program control. It is unlike any previously described molecular pathogenic mechanism. This model defines the nature of the therapy for these diseases, limits the potential set of therapeutically useful targets to a relatively small number of genes and leads to the unobvious conclusion that this includes the manipulation of certain "normal" genes is an appropriate approach for the treatment of AP diseases, thus, leading to a unique approach to therapy for the AP diseases of this invention. This model makes the selection of

targets for proposed therapy straightforward and accessible to anyone skilled in the art.

A preferred embodiment relates to the reprogramming of cell behavior through the manipulation of transcriptional regulators (TRs). The invention includes systemic treatment and compositions for such treatment, as well as in vitro manipulation of cells prior to transplantation of such cells with the host under treatment.

10 DESCRIPTION OF THE RELATED ART

Very recent studies involving the use of antisense oligonucleotides for treatment of cancer have been reviewed by Stein and Cohen, Cancer Res. 48:2659 (1988). Several types of antisense molecules have been screened for their ability to inhibit the synthesis of particular proteins using both intact cells and in vitro systems for protein synthesis (See Ld. and Paoletti, Anti-Cancer Drug Design 2:325, 1988). For example, agents with specificity for RNA transcribed from the myc gene have been reported to inhibit the proliferation of the human AML line HL60 (Wickstrom, et al., Proc. Natl. Acad. Sci. USA 85:1028 (1988) and normal T lymphocytes (Heikkila, et al., Nature 328:445 (1987), and oligodeoxynucleotides complementary to cyclin mRNA have been reported to suppress the division of 3T3 cells (Jaskulski, et al. 1988).

More recently, it has been found that in the treatment of cancer with ODNs against myb, the proliferation of leukemia cells was inhibited with an accompanying lower degree of inhibition against normal cells. (Calabretta et al, PNAS, 88, 2351, 1991.) Also,

it has been shown that transient inhibition in a leukemia cell line resulted with an ODN against myc; however, unfortunately, a comparable inhibition against normal cells occurred (Zon et al patent). This patent
5 also discloses inhibition of HIV replication using ODNs targeted to viral genes. Belenska et al (Science, 250, 997, 1990) have proposed the use of double stranded ODNs, binding to TR ligands as potential therapeutic agents for disease causing genes. They give blocking
10 of NF-kB binding to HIV enhancer as an example. The use of retroviral vectors carrying antisense oncogenes for the treatment of cancer is known.

The fundamental problem with the foregoing part is that it is based on the notion that the expression of
15 specific molecular abnormalities (altered regulation or mutation of endogenous genes or expression of exogenous genes) in the disease cells of these patients directly cause the clinical pathological features of the AP disease. It follows from such thinking that the
20 therapeutic strategies should be directed to attacking these molecular abnormalities.

In the case of cancer, contemplated therapy involving antisense expression vector ODNs have been directed to oncogenes in accordance with the
25 oncogene/anti-oncogene cancer model, or to growth factors expressed by cancer cells in accordance with the autocrine model. In the case of AIDS therapeutic strategies involving such agents being developed are directed toward blocking HIV expression and/or
30 infection. There are no counterpart causal agents identified to the other AP diseases. Hence the therapeutic approaches under development are more empirical.

According to the AP disease model the fundamental pathology causing the clinical pathological features of these disorders is both relational and dynamic. In stark contrast to the prior art, the therapy of the present invention involves manipulation of patterns of TR expression. The invention provides an entirely new approach to the treatment of said selected diseases and provides a rational, empirical basis for the design of novel agents. The therapeutic reprogramming of normal tissue involving ODNs is unprecedented.

SUMMARY OF THE INVENTION

In accordance with this invention, there is provided a method for reprogramming cell behavior to achieve therapeutic effects through manipulating patterns of TR expression.

Also provided is a method for treating an individual having an AP disease comprising administering to said individual an effective amount of a composition selected from the group consisting of an expression vector, a double stranded ODN, and an antisense ODN. Said composition must be capable of regulating expression of a TR. Said TR is expressed by the AP cells and further characterized by the fact that it exhibits a therapeutically useful change in said cell behavior in the Reprogramming Test of this invention (hereinafter more fully described). It is noted that when the AP disease is AIDS, said TR is not encoded by HIV. In the case of cancer, said TR is a Traitor Gene of this invention (more fully discussed hereinafter) and, preferably, excludes oncogenes, e.g. fos, myc, myb, rel, jun (in an altered form).

Another embodiment of this invention is a method for treating an individual having a clinical disorder comprising administering to said individual an effective amount of a composition selected from the group consisting of a double stranded ODN and an antisense ODN. The composition is capable of regulating expression of a TR. The TR is expressed by therapeutically relevant cells and is further characterized by exhibition of a therapeutically useful change in said cell behavior in the Reprogramming Test of this invention.

The invention revealed here primarily embodies a new type of therapy based on reprogramming cellular behavior. Collateral inventions, however, also follow including: (1) the diagnosis and/or staging of aberrant programming diseases by assaying for the expression of particular transcriptional regulators and their variants in diseased cells; and, (2) for any given aberrant program disease, the use of test agents in vitro for determining the optimum agent(s) for treating any particular patient.

Thus, there is provided a method for diagnosing or staging an AP disease comprising identifying the relevant subset of TRs expressed by AP cells from an AP patient. A method for selecting the most efficacious treatment regimen for an AP disease forms another embodiment. This embodiment comprises identifying the relevant subset of TRs expressed by AP cells from an AP patient. These embodiments are described more fully hereinafter.

In addition, the invention provides a method for treating therapeutically relevant cells from an individual having a clinical disorder prior to transplantation of the cells back into the individual (autologous transplant) embodiment. This embodiment comprises the steps of:

- a) obtaining therapeutically relevant cells from the individual and
- b) exposing the therapeutically relevant cells to a reprogramming amount of an ODN having a sequence complementary to a sequence of RNA transcribed from a TR regulated gene or double stranded ODN ligand of a transcriptional regulator present in the TR cells. In a preferred embodiment the cells are taken from prenatal tissue or from a different donor than the individual under treatment (allogeneic transplant).

Selection of the most efficacious treatment regimen for an AP disease forms another embodiment of this invention. This method involves removing and culturing AP disease cells from an AP disease patient with an antisense ODN specific to a TR from the relevant subset of TRs expressed by AP cells from an AP patient or a double stranded ODN to the DNA binding domain of such TR to determine optimal treatment.

In carrying out the methods of treating AP diseases of this invention it is critical to select the proper targets. Hence, an important embodiment of this invention is a method for the selection of a target for the treatment of an AP disease comprising (i) determining the subset of transcriptional regulators and their direct modifiers expressed by the aberrantly

programmed tissue, the corresponding normal tissue, or the constitutively self-renewing normal tissue or, alternatively, making a similar determination for any other normal tissue that is to be therapeutically manipulated in accordance with this invention; (ii) adding or subtracting expression of transcriptional regulator(s), or their direct modifiers, from cells to be therapeutically reprogrammed and the appropriate control tissue; (iii) scoring effect on cellular programming and selecting potential therapeutic agents according to the Reprogramming Test; (iv) testing effect of addition or subtraction of the function of particular transcriptional regulators, using the agents selected, (in an animal model system if the therapeutic agents are for systemic use), and (v) reducing or eliminating any undesirable side effects that might be produced by the potential therapeutic agents. This embodiment is described in detail hereinafter.

Exploiting specific cell type differences in target RNA for selecting differentially available sites for ODN binding forms another embodiment of this invention. This embodiment comprises a method for cell type dependant targeting of specific RNA transcripts comprising selecting an ODN capable of binding to and leading to the destruction of said RNA in the tissue to be therapeutically manipulated, but not in tissue where side effects are produced by destruction of said RNA. Exemplary is the use of an antisense ODN directed to cyclooxygenase RNA that selectively binds to and destroys said RNA in hematopoietic tissue while avoiding said RNA in gastrointestinal tissue.

All of the foregoing embodiments involve reprogramming of cell behavior to achieve therapeutic effects through manipulating patterns of TR expression.

DESCRIPTION OF THE PREFERRED EMBODIMENTS.

5 AP Disease Model and List

Definition of a "cellular program"

10 The coordinated appearance in cells of a cell type restricted pattern of gene expression over time that provides for a particular phenotype and as a result for the determination of the range of possible cellular responses to exogenous stimuli.

15 The fundamental program can be thought of as a differentiation program which in turn controls the subprogram responses of the cell to environmental and other exogenous cues where the subprograms include cellular viability (apoptosis) and proliferation.

Definition of an "Aberrant Programming Disease"

20 One in which the direct cause of the clinical disorder is the expression in the primary diseased cells of a differentiation program that does not normally exist. That is, there is an expression of normal genes that provide for
25 particular differentiated phenotype in abnormal combinations. The result is that these diseased cells become capable of expressing pathogenic

behaviors involving cellular differentiation, viability and proliferation. These attributes of the primary diseased cells can also induce pathologic change, in their tissue environment.

5. The term "direct cause" with respect to pathogenesis is to be distinguished from "risk factors." Typically an AP Disease will be associated with numerous risk factors that in various combinations appear to "cause" the appearance of the disease. In fact, however, they
10 cause the changes in the pattern of transcription regulator (TR) expression and chromatin domain availability which in turn causes the disease. This is important because programs can evolve and can become independent of any risk factors involved in their
15 induction. Risk factors include mutagenic events, viruses, chromosomal abnormalities, genetic inheritance, and diet.

Aberrant programming disorders can be manifested as either a hyperplastic or a hypoplastic (degenerative)
20 disease or a combination of both.

Examples of diseases where the aberrant program phenotype is expressed:

Cancer

Myeloproliferative Diseases

- 25 - polycythemia vera
 - agnogenic myeloid metaplasia
 - essential thrombocytosis

Myelodysplasias

- refractory anemia
 - refractory anemia with ringed sideroblasts
 - refractory anemia with excess blasts
 - refractory anemia with excess blasts in
- 5 transition

Atherosclerosis

AIDS-related complex

AIDS

Molecular Model

10 According to the molecular model set forth herein,
the basic disease causing entity in the AP diseases is
a specific type of relational alteration among certain
cellular components involved in program control. It is
unlike any previously described molecular pathogenic
15 mechanism. This model defines the nature of a novel
therapy for these diseases, limits the potential set of
therapeutically useful targets to a relatively small
number of genes and leads to the unobvious conclusion
that the manipulation of certain "normal" genes is an
20 appropriate approach for the treatment of AP diseases,
in this way the model makes the reduction to practice
of the proposed therapy straightforward and accessible
to anyone skilled in the art.

Specifically, the essential molecular pathology in
25 the AP diseases consists of changes in the
interdependent patterns of TR expression and/or
chromatin domain availability for transcription. In
turn, these relational alterations provide for the
expression of abnormal cellular programs involving

cellular differentiation which are pathogenic. Particular TR or certain molecules involved with the control of domain status may be structurally abnormal. However, these are not necessarily useful targets for
5 therapeutic intervention.

Tenets of the model relevant to the development of specific therapy:

A) Those true of both normal and aberrant programming:

10 1) The pattern of domain availability determines the possible range of genes that can be expressed in the cell and, therefore, limits the range of cellular programs that can be
15 expressed.

2) The pattern of TR expression is the molecular equivalent of a programming code. By analogy with language particular combinations of TR (letters) working as a unit (words) regulate
20 the expression of sets of genes in a coordinate fashion while the complete set of TR combinations used in any given cell (sentence) determines which of the possible phenotypes the cell will expressed, and therefore the overall
25 character of the cell's differentiation program (see Table I for more details where cancer is used as an example).

3) Only a subset of the total number of TRs involved in the control of cellular
30 differentiation for the total organism are

expressed in any given cell type and they are few in number.

5 4) Similar effects on particular patterns of gene expression (programming) can be achieved by more than one specific combination of -TR (synonyms).

10 5) The specific functional consequences of a particular TR's being expressed is context-dependent. That is, its effects on cellular programming depends both on which other TR it combines to regulate a particular set of genes (what words it appears in) and on the total set of different TR combination expressed by the cell (the sentence).

15 B) True of AP cells but not normal cells:

1) The combinations of TR seen in AP cells is different from that seen in any normal cell (the sentence is not expressed by any normal cell).

20 2) The specific functional consequences of any given particular TR being expressed in an AP cell, therefore, will be different from the consequences seen in a normal cell.

25 3) AP cells, therefore, express a cellular differentiation program that is different from any normal differentiation program. As a result AP cells express pathogenic behaviors resulting from their altered differentiation, viability and proliferation characteristics.

4) Hence, equivalent manipulations of the expression of a given TR in normal cells vs. aberrantly programmed cells can produce differential effects on cellular behavior. This can form the basis of therapeutic intervention.

5) The subset of TRs expressed by any AP cell is expected to include TR not expressed by the corresponding normal cells and/or conversely. These TRs within the AP cells will be normal TRs ectopically expressed or modified (alternate splicing promoter use or post-translational modification) or mutated to a TR with altered binding properties.

Nature of Targets

TRs are the primary targets for therapeutic manipulations based on the model. They may be manipulated directly or indirectly through molecules such as tyrosine kinase, that can effectively change a TR of one type to another through structural alterations such as phosphorylation.

Nature of Therapeutic Intervention

The basis of the novel therapy is to differentially change the pattern of gene expression in AP cells by altering the pattern of TR expression. The model states that the specific functional consequences of the expression of any given TR is context-dependent. It therefore follows that the same TR present in both normal and AP cells can be manipulated in the same way and a different impact on cellular behavior obtained.

A TR expressed only by the AP cells, however, also may be targeted. The end result is that the pattern of gene expression in the AP cells lose at least a substantial portion of their disease-producing activity. This can be manifested in numerous possible ways including death of the AP cells, a change in their differentiation status with a concomitant change in the production of disease-producing factors or to a loss of proliferative potential.

10 The number of transcriptional regulators that will have to be manipulated in any given cell type will be very small. There are estimated to be 30,000 to 100,000 genes in the human genome distributed over 3×10^9 bp of DNA. In any given cell type approximately 10,000 genes
15 can be shown to be expressed. Greater than 90% of these are expressed by many cell types and the large majority of these are referred to as "housekeeping genes."

Typically, the number of genes that can be shown to be differentially expressed in any given cell type
20 account for only a few hundred. It is these genes that make the difference between liver cells and brain cells, for example. The large majority of these are directly involved in carrying out the functions that characterize the cell type. Liver cells, for example, express a wide
25 range of enzymes that are involved in ridding the body of many types of chemicals. The genes of interest for the purposes of this patent are the small subset of genes coding for molecules involved in the differential regulation of cell type specific genes. In particular,
30 transcriptional regulators and their direct modulators. The latter includes, for example, certain tyrosine kinases, that can modify a particular transcriptional

regulator and, in effect, change it to a functionally different transcriptional regulator. (Berk Biochem Biophys. Actn. 1009, 103, 1989) For the purposes of this invention transcriptional regulators are defined
5 as molecules that bind to specific DNA sequences variably expressed by different genes and/or to other transcriptional regulators at least one of which must bind to specific DNA sequences. As a result they control the levels of gene expressions by means of
10 modulating RNA polymerase activity. The transcriptional regulators may be of either endogenous or exogenous origin. They may either be normal or be mutated.

The ability of transcriptional regulators to variably interact with each other provides the basis for
15 a combinational regulatory system. This allows a very small number of transcriptional regulators to control the expression of a large number of genes in various patterns. Particular sets of genes being controlled at any given time by a certain subset of the
20 transcriptional regulators being expressed by the cell. Each transcriptional regulator subset, therefore, is a programming code or an instruction or a "word" that directs the expression of a particular gene set. The entire pattern of gene expression being expressed by a
25 given cell type can be thought of as a sentence, since only certain words can appear together.

A general role for combinatorial regulation being involved in eukaryotic gene expression has been previously postulated by several investigators.
30 (Scherrer, and Marcand J. Cell Phys 72, 181, 1968; Sherrer Adv. Esp. Med. Biol. 44, 169, 1924; Gierer Cold Spring Harbor Symp Quant Biol 38; 951, 1973; Stubblefield J. Theor Biol 118, 129, 1986, Bodnar J.

Theor Biol 132, 479, 1988) Lin and Riggs (Cell 4, 107, 1975), demonstrated using biophysical arguments the impossibility of having a separate regulator for every gene in a eukaryotic cell. Combinatorial regulation models of eukaryotic gene expression generally postulate multiple levels of regulation in addition to transcription. In principle, these models show how theoretically 100,000 genes could be selectively controlled by as few as 50 regulatory molecules only a small subset of which would operate at the level of what is defined here as transcriptional regulators. Bodnar J. Theor. Biol. 132, 479, 1988.

The actual number of human transcriptional regulators are estimated to number on the order of somewhere in excess of 100. (Table II lists those that have been described in the literature.) Many, however, are known to be expressed only in certain cell types. Since just a few hundred genes determine the differences between particular differentiated cell types and the large majority of these determine the particular functional features of the cell, only a very small number of these can be regulator gene products.

It follows, therefore, that the number of regulators that must be manipulated to achieve the effects stipulated by this invention for any given application is small and can be managed with comparatively modest effort. It also follows from the notion of combinatorial regulation that not all the transcriptional regulators expressed by a given cell type need to be known before this invention can be practiced.

The present inventor has found that antisense p53 oligonucleotides can inhibit the proliferation, including the blocking of stem cell self-renewal, and ultimately kill primary human leukemic blasts while not producing similar effects on fresh normal bone marrow cells. This unobvious result indicates that the interactive mechanisms for detecting, interpreting and responding to environmental informational molecules involved in regulating cell differentiation and proliferation and viability in AP cells are so altered from normal in terms of their dynamic interactions (involving signal transduction and interpretation) that the inhibition of a single gene or set of genes coding for proteins involved in this process by antisense oligonucleotides is sufficient to change the impact of the informational molecules so a change in cellular programming such as cellular death or growth inhibition program can be selectively instituted in AP cells. The term "traitor genes" is used herein to describe those genes in AP cells that may be suitable for targeting for inhibition with antisense molecules in accordance with the present invention. Suitable target or traitor genes may themselves either be functionally abnormal or be normal but function to maintain the pathological phenotype AP cells as part of an abnormal pattern of gene expression. Such treatment results in differential programming of AP cells, but not their normal counterparts over a selected dose range. In the preferred embodiment the Traitor Genes to be targeted are TRs.

The concentration of oligonucleotide to be used may vary, depending upon a number of factors, including the type of cancerous cells present in the marrow, the type, and the specificity of the particular antisense

oligonucleotide(s) selected, and the relative toxicity of the oligonucleotide for normal cells. Although the present inventor has observed significant AP cell programming at oligonucleotide concentrations in extra-cellular fluid as low as 1 nanomolar, optimal inhibition was observed at concentrations of at least 10 nanomolar in the model system described below. The upper limit of the dosage range is dictated by toxicity and therapeutic efficacy, and, generally will not exceed 5 micromolar. With the aid of the techniques set forth in the present disclosure, those of skill in the art should be able to determine the optimal concentration to be used in a given case.

"Hardware" for Reduction to Practice

Using established techniques, assays and agents, the following capabilities can be readily acquired. These can be used by anyone skilled in the art to reduce the primary and collateral inventions to practice.

- 1) Assays for transcriptional regulators and their direct modifiers.

Preferred assays: RNA in situ hybridization (Lum Biotech. 4, 32, 1986) or PCR (Block, Biochem 30, 2735, 1991) or metabolic labelling (Ausubel et al (eds.) Current Protocols in Molecular Biology, John Wiley NY, 1989 (updated semiannually)) for detecting expression at the protein level.

Purposes:

To establish the subset of the known transcriptional regulators or their direct modifiers that are expressed by a particular cell type. This will serve the following functions:

- 5 a) the determination of the subset of transcriptional regulators, or their direct modifiers, that are targets to be manipulated in the reduction to practice;
 - 10 b) the evaluation of the effectiveness of potential therapeutic agents in adding or subtracting the expression of a particular transcriptional regulator or its direct modifier cells;
 - 15 c) the diagnosis and/or staging of a particular aberrant program disease;
 - 20 d) the determination of the optimum therapeutic agent(s) in clinical practice, when there are more than one option for a given disease.
- 2) Agents for adding or subtracting the expression of particular transcriptional regulators or their direct modifiers in cells to be therapeutically manipulated.
- 25 a) Antisense oligonucleotides (Zon, Pharmaceut. Res., 5, 539, 1988).

These agents can be used to subtract the expression of particular genes from cells.

Design of "test" antisense oligonucleotides

- 5 i) Using a computer program such as "Oligo" (Rychik and Rhoads, Nucl. Acids Res., 17, 8543, 1989) select a set of antisense oligonucleotides that bind to the RNA target of choice that have the following characteristics: (1) length between 10 and 35 bases with 20 being generally used; (2) negligible self-interaction (self-dimers and hair pins) under physiologic conditions; (3) melting temperature $\geq 40^{\circ}\text{C}$ under physiological conditions; and (4) no more than 40% of the oligonucleotide being a run of guanines or cytosines);
- 20 ii) Using a reference such as Genbank ensure that the antisense oligonucleotide has $\leq 85\%$ homology with the RNA transcripts of other genes. An exception to this is where an antisense oligonucleotide is selected on the basis of its ability to bind to more than one member of a transcriptional regulator family (such as the homeobox genes) on the basis of sequence homology.
- 25
- 30 b) Establishment of "prototype therapeutic" antisense oligonucleotide from a set of test antisense oligonucleotides. These prototype

compounds will be used in the reduction to practice.

- 5 i) Synthesize test antisense oligonucleotides using standard procedures, for example, those for producing phosphorothioates (Vu et al, Tetrahedron Lett, 32, 3005, 1991).
- 10 ii) Using assays for transcriptional regulators or their direct modifiers select prototype therapeutic antisense oligonucleotides out of the set of test compounds on the basis of shutting down expression of the
- 15 target gene in the cell types to be therapeutically manipulated. In practice, the same set of prototype agents capable of shutting down target gene expression in a variety
- 20 of cell types could be used in the Reduction to Practice, Step 2, hereinafter, for multiple therapeutic objectives.
- 25 b) Synthetic double-stranded oligonucleotides that are ligands for the DNA binding domain of one or more transcriptional regulators. (Wu et al, Gene, 89, 203, 1990)

30 Prototype therapeutic agents of this type for use in the reduction to practice will correspond to actual gene sequences to which the transcriptional regulator(s) will have been

shown to bind using standard techniques such as the gel mobility shift assay. (Ausubel et al (eds.) Current Protocols in Molecular Biology, John Wiley NY, 1989 (updated semiannually).)

5 c) Expression vectors

10 In the preferred embodiment a recombinant viral vector will be used (Miller and Rosman, Biotech, 7, 980, 1989) that carries the complete coding sequence of the transcriptional regulator or its
15 direct modifier. This will provide for expression of the regulator or modifier in the cells of interest. It will be constructed and tested using standard methods. (Ausubel et al, supra) Alternatively, the viral vector will
20 carry a sufficiently long antisense sequence to such a regulator or modifier to provide for the blocking of expression of the target gene in the cells of interest.

3) Preparation of Tissue

20 The preferred tissue is primary explant or early passaged. It will be acquired using standard surgical procedures. Tissue processing for culture and/or heterotransplant will be according to established methods. Culture
25 conditions for the disordered cells from the various aberrant program diseases or their normal counterparts are referenced in Table III. These references also provide information on acquiring and processing the appropriate cells.

30 Uses to provide the source material for:

- a) determining the subset of the known transcriptional regulators or their direct modifiers that are expressed by a particular cell type.
- 5 b) practicing the collateral inventions; that is, diagnosis and staging an aberrant program disease or for selecting optimal treatment in clinical practice.
- 10 c) evaluating possible adverse effects of treatments for aberrant program diseases on cultures of the three major constitutively self-renewing tissues (bone marrow, gastrointestinal epithelium, and skin). These cultures will also be used in some of the reductions to practice involving therapeutic manipulations of normal tissue. Culture conditions, Table IV.
- 15 d) The other cultures and heterotransplants to be used in the reduction to practice.
- 20 4) Discrimination of normal vs malignant cells in a mixed population.

Standard in situ hybridization procedures for detecting chromosome and/or translocation specific changes will be utilized. (Trask Trends in Genet. 7, 149, 1991).

- 25 5) Establish assays for scoring effects of manipulating transcriptional regulator function or their direct modifiers on cellular programming.

a) Aberrant program disease tissue -

By definition the affected cells in these disorders express abnormal patterns of gene expression that produce the characteristic clinicopathologic features. Both of these can be monitored using established molecular and cellular techniques. The specific parameters to be assayed for each of the types of aberrant program disease given as examples are shown in Table III.

b) Normal tissue -

Reprogramming normal cell behavior where the relevant programs are differentiation, proliferation and viability could serve a variety of therapeutic uses. These would include but not be limited to certain in vitro and systemic treatments: (1) expansion of normal cell numbers in vitro prior to transplantation; (2) promotion of the growth of gastrointestinal cells in the treatment of peptic ulcers and inflammatory bowel disease; (3) liver regeneration, for example, following partial destruction by a virus or toxic chemicals; (4) expansion of one or more hematopoietic cell lineages for a variety of clinical purposes including reconstitution of immune function in immunodeficiencies, counteracting the effects of agents toxic to bone marrow and in fighting infection.

All of these changes in normal cellular programming can be readily assessed using established techniques.

B) Reduction to Practice

5 Step 1) Determine the subset of
transcriptional regulators, and their
direct modifiers, expressed by the
aberrantly programmed tissue, the
corresponding normal tissue, and the
10 constitutively self-renewing normal
tissue. Alternatively make a similar
determination for any other normal
tissue that is to be therapeutically
manipulated in accordance with this
15 invention.

Step 2) Add or subtract expression of
transcriptional regulator(s) or their
direct modifiers from cells to be
therapeutically reprogrammed and the
20 appropriate control tissue, as
previously specified.

a) Addition - Use expression vector to insert
expressible gene for a particular
transcriptional regulator or a direct modifier
25 of a transcriptional regulator into aberrantly
programmed cells. The inserted gene will be one
that is expressed by the corresponding normal
cells, but not by the aberrantly programmed
cells.

30 b) Subtraction -

5 i) can be achieved by the use of antisense oligonucleotides directed to the RNA of a particular transcriptional regulator or direct modulator or double-stranded oligonucleotide ligands for DNA binding domain of one or more transcriptional regulators

10 Using prototype antisense oligonucleotide(s) or double-stranded oligonucleotides block function of specific transcriptional regulator(s) in aberrantly programmed cells or normal cells to be therapeutically manipulated through reprogramming. Alternatively use an antisense
15 oligonucleotide directed to a direct modifier of a transcriptional regulator.

20 ii) Using expression vector carrying antisense DNA directed to a particular transcriptional regulator or a direct modifier of a transcriptional regulator, install the new gene in aberrantly programmed cells. The therapeutic effect will be determined in advance through the
25 use of an antisense oligonucleotide.

Step 3) REPROGRAMMING TEST:

Using the methods and procedures described in the "Hardware for Reduction to Practice" and using the information given in Tables III and
30 IV, perform the following functions.

- 5 a) Utilize appropriate culture conditions for normal cells to be therapeutically reprogrammed' or for AP disease, the AP cells plus the corresponding normal cells and constitutively self-renewing normal tissues (gastrointestinal, bone marrow, skin);
- 10 b) For AP disease, assay one or more pathogenic features of AP cells such as those shown in Table III, according to established procedures;
- 15 c) Treat cultures with prototype agent with reprogramming potential (as oligonucleotides to TR, as oligonucleotide ligands for TR, or expression vectors).
- 20 d) Score changes in programming and choose those agents that are therapeutically useful; for example:
- 25 1) cancer, myelodysplasiac and myeloproliferative syndrome and atherosclerosis - kill AP cells;
- 2) AIDS, regenerate CD4⁺ lymphocytes;

3) Expand normal hematopoietic stem cells for bone marrow transplant.

Step 4) Test effect of addition or subtraction of the function of particular transcriptional regulators using the agents selected in an animal model system if the therapeutic agents are for systemic use.

Because of the need for a high degree of target homology with the corresponding human transcriptional regulator or its direct modulator the animals will of necessity nearly always be non-human primates.

In the case of evaluating agents for the treatment of aberrant program diseases the animal may either be afflicted with the disease and both the efficacy of the treatment and the side effect documented or the animal may be normal and only the side effects tested.

Step 5) Any undesirable side effects that might be produced by the potential therapeutic agents can be reduced or eliminated in several possible ways, all of which can be implemented using existing technology.

a) Antisense oligonucleotides

Figure I demonstrates that there are cell type specific differences in effects of particular antisense oligonucleotides targeted to different sites on specific RNA transcripts on cell behavior. Such differences can be used to select antisense oligonucleotides that produce the desired therapeutic effects with minimal undesirable side effects.

b) Double-stranded oligonucleotide ligands

Typically more than one transcriptional regulator can bind to the same double-stranded DNA sequence, but with variable affinities. It is, therefore, possible to change the competitive inhibitor effect of such an agent relative to the potential set of target transcriptional regulators by introducing base changes. These can include mismatches. The melting temperature of the two resulting strands, however, must be $\geq 40^{\circ}\text{C}$ under physiologic conditions. The effect of such changes, therefore, can produce a more favorable therapeutic index.

c) Expression vectors

The levels of expression and efficiency of gene transfer can be readily adjusted on a tissue specific basis by changes in the viral envelope and/or the promoter/ enhancer combination used to achieve gene expression.

Demonstration of the Reduction to Practice with a P53 Target

Step 1 -

It is known that p53 is expressed by primary human
5 leukemia blast cells using the metabolic labeling
technique (Smith, et al., J. Exp. Med. 164, 751, 1986.)

Step 2 -

A set of four different phosphorothioate antisense
oligonucleotides directed to p53 RNA were prepared using
10 an Applied Biosystems, Inc. (ABI) DNA synthesizer (Model
380B) according to the manufacturer's protocols. An
antisense oligonucleotide against the HIV rev gene was
used as a negative control. The sequences are set forth
in the Sequence Listing hereinafter as SEQ ID NOS:1-4.
15 These were used to treat primary human leukemic blasts,
normal human bone marrow, normal human circulating T-
lymphocytes, normal adult human gastrointestinal
epithelium, normal human fetal gastrointestinal
epithelium and Rhesus monkey T-lymphocytes. Destruction
20 of p53 RNA by the antisense p53 oligonucleotides was
documented using PCR and/or dot blotting.

Step 3 -

The following effects of the antisense p53
oligonucleotides on cellular programming were evident
25 from the results found.

- 1) They can irreversibly block the proliferation
of, block stem cell self-renewal, or kill human
cancer cells. This coupled with the lack of

toxic effects on normal tissue indicates these agents can have a role in the treatment of cancer. (See Tables V-VII).

- 5 2) They promote the proliferation of gastrointestinal epithelium, indicating a role in the treatment of peptic ulcer and inflammatory bowel disease (FIGURE I). The suppressive effect of these agents on mature lymphocyte (Table IX) proliferative also
10 supports their role in diseases such as inflammatory bowel disease that have an autoimmune component.
- 15 3) The data also demonstrates that there are cell type specific differences in responses to antisense oligonucleotides targeted to different sites on RNA transcripts of the same gene (FIGURE I). This provides a basis for optimizing therapeutic effects and for minimizing undesirable side effects.
- 20 4) These results support the general principle that antisense oligonucleotides directed to a transcriptional regulator can be used to expand particular normal adult or fetal tissues in vitro that could then be used for various
25 medical purposes including transplantation (FIGURE I).
- 30 5) The cell type dependency of the effects of particular antisense oligonucleotides directed to a transcriptional regulator support the cellular program model in general and the aberrant program model in particular.

Step 4 -

The ability of the antisense p53 oligonucleotides to recognize the p53 RNA of Rhesus monkeys was demonstrated by showing a similar inhibitory effect on mature T-cell proliferation for both Rhesus and human cells (Table IX).

Two Rhesus monkeys weighing 8.9 kg and 6.8 kg were infused with 52.5 mg and 75.8 mg of the OL(1)p53 antisense oligonucleotide (SEQ ID NO:4) which was radiolabelled over four hours. In keeping with rodent data, tissue distribution analysis showed substantial oligonucleotide uptake compared to the levels needed to block p53 expression. Excretion studies demonstrated retention of the infused agent for more than two weeks. During this time and subsequently, the animals were extensively monitored for signs of toxicity and none were seen.

Step 5 -

Since no unacceptable side effects were produced in the monkeys, it has not been necessary to modify the antisense oligonucleotides.

The antisense oligonucleotide selected for practice of the invention may be any of the types described by Stein and Cohen, Cancer Research 48:2569-2668 (1988), and including without limitation, unmodified oligodeoxynucleotides, ethyl- or methyl-phosphonate modified oligodeoxynucleotides, phosphorothioate modified oligonucleotides, dithioates, as well as other oligonucleotide analogs, including those incorporating ribozyme structures, and oligoribonucleotides such as

those described by Inove et al., Nucleic Acids Res. 15:6131 (1987); and Chimeric oligonucleotides that are composite RNA, DNA analogues (Inove, et al, FEBS Lett. 2115:327 (1987). Oligonucleotides having a lipophilic backbone, for example, methylphosphonate analogs with ribozyme structures, may prove advantageous in certain circumstances; these molecules may have a longer half-life in vivo since the lipophilic structure may reduce the rate of renal clearance while the ribozyme structure promotes cleavage of the target RNA. Gerlach, Nature 334:585 (1988).

The oligonucleotides may be formulated into pharmaceutical compositions and administered using a therapeutic regimen compatible with the particular formulation. As described further below, with the aid of present disclosure, those of skill in the chemotherapeutic arts should be able to derive suitable dosages and schedules of administration for any of a number of suitable compositions that contain the compounds. Thus, pharmaceutical compositions within the scope of the present invention include compositions where the active ingredient is contained in an effective amount to kill the cells of the cancer without causing unacceptable toxicity for the patient. However, a preferred dosage comprises that which is sufficient to achieve an effective blood concentration of between about 1 and about 5 micromolar. Although a preferred range has been described above, determination of the effective amounts for treatment of each type of tumor may be determined by those of skill in the art of chemotherapeutic administration.

In addition to the antisense oligonucleotide compounds, the pharmaceutical compositions of the

invention may contain any of a number of suitable excipients and auxiliaries which facilitate processing of the active compounds into preparations that can be used pharmaceutically. Preferably, the preparations will be designed for parental administration. However, compositions designed for oral or rectal administration are also considered to fall within the scope of the present invention. Preferred compositions will comprise from about 0.1 to about 1% by weight of the active ingredients.

Suitable formulations for parental administration include aqueous solutions of the active compounds in water-soluble or water-dispersible form. Alternatively, suspensions of the active compounds may be administered in suitable lipophilic carriers. The formulations may contain substances which increase viscosity, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran. Optionally, the formulation may also contain stabilizers. Additionally, the compounds of the present invention may also be administered encapsulated in liposomes. The oligonucleotide, depending upon its solubility, may be present both in the aqueous layer and in the lipidic layer, or in what is generally termed a liposomic suspension. The hydrophobic layer, generally but not exclusively, comprises phospholipids such as lecithin and sphingomyelin, steroids such as cholesterol, more or less ionic surfactants such as diacetylphosphate, stearylamine, or phosphatidic acid, and/or other materials of a hydrophobic nature.

TABLE I

Analogy with Language

The following analogy with language illustrates the essential nature of the model of clinical cancer given in the patent application and the basic rationale for using antisense oligonucleotides directed against the indicated target or traitor genes as therapeutic agents. It should be clear that this is a novel, inventive and useful approach.

10 RULES:

<u>Biology</u>	<u>Language Equivalent</u>
The instructions for a particular pattern of gene expression (program) where key programs are differentiation, viability and proliferation	word
Transcriptional Regulators (or any of the other types of regulators listed as target or traitor genes)	letters
Programmed cell death	nonsense letter combination
Malignant cells have different program instructions than corresponding normal cells and normal cells in general	malignant cells express unique words

Normal cells at different stages of differentiation express different program instructions than other cell types

different normal cell types have their own vocabulary

ABL or nearly all the letters used by malignant cells are structurally normal and appear in normal cells

the alphabets of normal and malignant cells are essentially the same

As particular programs unfold, the pattern of regulators expressed changes

cells express different words at different program stages

Note: The words used in the following examples have only a loose correlation to actual cellular behaviors or programs.

Hypothetical Example

	<u>Cell Type 1</u> (e.g. liver)	<u>Cell Type 2</u> (e.g. kidney)
Normal	retard	stop
Low grade malignant	start	swarm
High grade malignant	spread	grow

Comments - Table I (cont.)

I. ANALOGY WITH BASIC CLINICOPATHOLOGIC MECHANISMS

5 a) "T" and "P" in normal cell type 2 but not in malignant type 1 could be considered analogous antioncogenes since they must be deleted for malignant progression. That is, for the word "stop" to be changed to the word "swarm". These deletions must occur along with the deletion of "o" and the addition of "w", "a", "r" and "m". The same letter "p", however, appears in 10 the high grade malignant type 1 cell, while "t" appears in the low grade form. This fits the observations that antioncogenes are far from universally deleted in human cancers, that multiple genetic changes appear to be involved in carcinogenesis and that clinical cancers 15 typically evolve phenotypically.

b) "m" and "w" could be considered analogous to "oncogenes" since they are required for "stop" evolving to "swarm" and they are not expressed in other normal adult cells. Alternatively, "m" and "w" could be 20 normally only expressed at the embryonic-fetal stage of development.

c) "s" becomes expressed in the malignant forms of type 1 cells (ectopic expression) while it is normally expressed in type 2, but not type 1.

25 II. ANALOGY WITH ANTISENSE OLIGONUCLEOTIDE TREATMENT STRATEGY

a) Inhibition of "t" expression will kill low grade type 1 cells but not normal cell types 1 and 2, because "start" becomes "sar" which is not a word, but

"retard" and "stop" become "read" and "sop" respectively which are both words.

5 b) Blocking "m" but not "w" will kill malignant cell type 2 at the low grade phase since "swarm" minus "m" becomes "swar" which is not a word; but "swarm" minus "w" becomes "rams", a word.

10 d) Knocking out "a" will kill low grade 1 and 2 and high grade 1, but it also kills normal cell type 1. So antisense inhibition of "a" might be useful for purging bone marrow of malignant cell type 1 or 2 but not for systemic treatment.

15 e) Deletion of "r" would not kill normal cell type 1 ("retard" becomes "date"), but it would kill three of the four malignant cell types. The exception being low grade 1 where "start" becomes "sat".

 f) Removal of "e" kills normal and high grade type 1, so it would not be expected to be a good target for systemic therapy.

20 g) Of the remaining letters elimination of "d" or "g" will not result in the death of any of the cell types; removal of "s" will kill high grade 1, but none of the other cell types it appears in; blocking "o" will kill both malignant forms of type 2; and inhibition of "p" will kill high grade 1 but not normal type 2.

TABLE II
Human Transcriptional Regulators

<u>Members</u>	<u>Family</u>	<u>Where known to be expressed</u>	<u>Representative Reference</u>	<u>Possible Direct Modifications</u>	<u>Reference</u>
p 53	---	proliferating mature T and B lymphocytes, numerous types of cancer	Kern, et al., Sci. 252, 1708, 1991.	phosphorylation	Smith, et al., J. Exp. Med. 164, 751, 1986.
A20	---	endothelial cells	Opipari, et al., J. Biol. Chem. 265, 14705, 1990.	---	---
AP-1	---	liver	Metzger, et al., J. Biol. Chem. 265, 9978, 1990.	---	---
AP-2	---	cell lines	Comb and Goodman, Nucl. Acids Res. 18, 3975, 1990.	---	---
AP-4	---	cell lines	Hu, et al., Genes and Dev. 4, 1741, 1990.	---	---
ATF1-8	ATF	cell lines	Hoeffler, et al., Mole. Endocrine 5, 256, 1991.	---	---
C/EBP	---	liver	Friedman and Muknight, Genes and Dev. 4, 1410, 1990.	---	---

TABLE II (CONTINUED)

CHF.10	---	cell lines	Pannuti, et al., Nucl. Acids Res. <u>16</u> , 4227, 1988.	---	---
CHF.12	---	cell lines	Pannuti, et al., Nucl. Acids Res. <u>16</u> , 4227, 1988.	---	---
(PE-RF)	---	fetal tissue, cell lines	Maekawa, et al., EMBOJ. <u>8</u> , 2023, 1989.	---	---
CBER	---	cell lines	Huchardt, et al., J. Virol. <u>64</u> , 4296, 1990.	phosphorylation	Hoeffler, et al., Mol. Endo. <u>5</u> , 256, 1991.
E12	---	cell lines	Mosse, et al., Cell <u>56</u> , 777, 1989.	---	---
F47	---	cell lines	Mosse, et al., Cell <u>56</u> , 777, 1989.	---	---
E2A	---	all blasts	Kamps, et al., <u>60</u> , 535, 1990.	---	---
FRF1	---	cell lines	Clark, et al., Genes Dev. <u>2</u> , 991, 1988.	---	---
EGR 1-3	EGR	cell lines, PMA induced mononuclear cells	Rangnekar, et al., Nucl. Acids Res. <u>18</u> , 2749, 1990.	---	---

TABLE II (CONTINUED)

EGF 1,2	ETS	cell lines	Watson, et al., PNAS <u>85</u> , 7862, 1988.	---	---
ETS 1,2	ETS	T lymphocytes, fetal liver, astrocytes	Bhat, et al., PNAS <u>87</u> , 3723, 1990.	---	---
GLI-1-3	GLI	embryonal carcinoma, myometrium, testis, placenta	Ruppert, et al., Mol. Cell. Biol. <u>8</u> , 3104, 1988.	---	---
HKP1-4	HKP	testis, placenta, kidney, colon, lung, brain, embryonal carcinoma	Ruppert, et al., Mol. Cell. Biol. <u>8</u> , 3104, 1988.	---	---
HOX 1.4, homeobox 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 5.1, 5.2, 5.4, 6.1, 6.2, 7		cell lines, embryos			
HPFp1-9	HPFp	placenta	Bellefroid, et al., DNA <u>8</u> , 377, 1989.	---	---
H-plk	---	placenta	Kato, et al., Mol. Cell. Biol. <u>10</u> , 4401, 1990.	---	---
HS1	---	lymphocytes	Kitamura, Nucl. Acids Res. <u>17</u> , 93167, 1989.	---	---

TABLE II (CONTINUED)

hPEF	---	lymphocytes	Liou, et al., Sci. 247, 1581, 1990.	---
I ₃ P	---	placenta	Zabel and Baerle, Cell 61, 255, 1990.	---
JSGF1-3	---	cell lines	Pine, et al., Mol. Cell. Biol. 10, 2448, 1990.	---
JUNE	JUN	cell lines	Memura, et al., Nucle. Acids. Res. 18, 3047, 1990.	---
C-JUN	JUN	cell lines	Memura, et al., Nucle. Acids. Res. 18, 3047, 1990.	---
JUN-D	JUN	cell lines	Memura, et al., Nucle. Acids. Res. 18, 3047, 1990.	---
FB	homeobox	cell lines	Kongsuwan, et al., EMBOJ. 7, 2131, 1988.	---
lyl-1	---	cell lines	Wellentin, et al., Cell 58, 77, 1989.	---
MAX	---	cell lines	Blackwood and Eisenman, Sci. 251, 1211, 1991.	---

TABLE II (CONTINUED)

WFF-1	---	cell lines	Baldwin, et al., Mol. Cell. Biol. <u>10</u> , 1406, 1990.	---	---
A-myb	myb	cell lines	Normora, et al., Nucl. Acids Res. <u>16</u> , 11075, 1988.	---	---
B-myb	myb	cell lines	Normora, et al., Nucl. Acids Res. <u>16</u> , 11075, 1988.	---	---
C-myb	myb	cell lines, hematopoietic tissue	Normora, et al., Nucl. Acids Res. <u>16</u> , 11075, 1988.	---	---
C-myc	myc	cell lines, hematopoietic tissue	Gazin, et al., EMBOJ. <u>3</u> , 383, 1984.	---	---
L-myc	myc	placenta, lung cancer	Kaye, et al., Mol. Cell. Biol. <u>8</u> , 186, 1988.	---	---
H-myc	myc	neuroblastoma	Slaman, et al., Sci. <u>232</u> , 768, 1986.	---	---
myf5	---	muscle	Braun, et al., Nature <u>346</u> , 663, 1990.	---	---

TABLE II (CONTINUED)

11F-E1,2	11F-E	hematopoietic cells	Mignotte, et al., Nucl. Acids Res. <u>17</u> , 37, 1989.	---	---
11FE6	11F-E	hematopoietic cells	Colin, et al., J. Biol. Chem. <u>265</u> , 16729, 1990.	---	---
11F- μ E1	---	lymphocytes	Sen and Baltimore, Cell <u>46</u> , 705, 1986.	---	---
11F- μ E3	---	lymphocytes	Sen and Baltimore, Cell <u>46</u> , 705, 1986.	---	---
11FC1a	---	embryonic tissue, hematopoietic cells	Shannon, et al., Mol. Cell. Biol. <u>10</u> , 2950, 1990.	---	---
11FC1b	---	hematopoietic cells	Shannon, et al., Mol. Cell. Biol. <u>10</u> , 2950, 1990.	---	---
11F-IL6	---	monocytes	Akira, et al., EMBOJ. <u>9</u> , 1897, 1990.	---	---
11F- κ R	---	lymphocytes, cell lines	Ruben, et al., Sci. <u>251</u> , 1490, 1991.	---	---
11F-5	---	lymphocytes	Kobr, et al., Mol. Cell. Biol. <u>10</u> , 965, 1990.	---	---
225	---	cell lines, lymphocytes	Wright, et al., Sci. <u>248</u> , 588, 1990.	---	---

TABLE II (CONTINUED)

243	---	lymphocytes	Bours, et al., Mature 348, 76, 1990.	---	---
Oct 1	Oct	cell lines	Johnson, et al., Mol. Cell. Biol. 10, 1982, 1990.	---	---
Oct 2	Oct	cell lines	Johnson, et al., Mol. Cell. Biol. 10, 1982, 1990.	---	---
Oct. 3	Oct	embryonic	Scholer, et al., EMBOJ. 9, 2185, 1990 (murine)	---	---
Pit-1	---	pituitary	Chen, et al., Nature 346, 583, 1990.	---	---
PL1	homeobox	cell lines	Shen, et al., PNAS 86, 8536, 1989.	---	---
Pr1	homeobox	cell lines	Kamps, et al., Cell 60, 547, 1990.	---	---
Eh	---	hematopoietic cells, retinal cells	Lee, et al., Sci. 235, 1394, 1987.	phos- phoryla- tion	Yen, et al., Exp. Cell. Res. 192, 289, 1991.
PF-y	---	cell lines	Reith, et al., Cell 53, 897, 1988.	---	---
PF-x	---	lymphocytes	Reith, et al., Genes Dev. 4, 1528, 1990.	---	---

TABLE II (CONTINUED)

Rhombotin	---	cell lines	McGuire, et al., Mol. Cell. Biol. <u>9</u> , 2124, 1989.	---	---
ECF	---	fetal liver, hematopoietic cells, placenta	Beyley, et al., PNAS <u>86</u> , 10128, 1989.	---	---
Sp-1	---	cell lines	Pugh and Tjian, Cell <u>61</u> , 1187, 1990.	---	---
SPF	---	cell lines	Horman, et al., Cell <u>55</u> , 989, 1988.	---	---
T _H 1	---	cell lines	Chen, et al., EMBOJ. <u>9</u> , 415, 1990.	---	---
TCF-1	---	lymphocytes	Van de Wetering, et al., EMBOJ. <u>10</u> , 123, 1991.	---	---
TFE3	---	lymphocytes	Beckmann, et al., Genes Dev. <u>4</u> , 167, 1990.	---	---
VAU	---	hematopoietic cells	Katzav, et al., EMBOJ. <u>8</u> , 2283, 1989.	---	---
cfos	fos	hematopoietic cells	Runkel, et al., Mol. Cell. Biol. <u>11</u> , 1270, 1991.	phosphorylation	Barber and Verma, Mol. Cell. Biol. <u>7</u> , 2201, 1987.
fos-B	fos	cell lines	Munberg et al., Genes Dev, <u>5</u> , 1212, 1991	---	---

TABLE II (CONTINUED)

fra-2	fos	cell lines			
glucocorticoid receptor	steroid receptor super family	lymphocytes and numerous other cell types	Hishina et al, PNAS, 87, 3614, 1990 (chicken)	—	—
androgen receptor	steroid receptor super family	male reproductive organs, muscle	O'Malley, Mole Endocrin., 4, 363, 1990	—	—
progesterone receptor	steroid receptor super family	female reproductive organs	O'Malley, Mole Endocrin., 4, 363, 1990	—	—
estrogen receptor	steroid receptor super family	female reproductive organs	O'Malley, Mole Endocrin., 4, 363, 1990	—	—
estrogen related receptors	steroid receptor super family	female reproductive organs	O'Malley, Mole Endocrin., 4, 363, 1990	—	—

TABLE II (CONTINUED)

retinoic acid receptor	steroid receptor super family	hematopoietic cells, epithelial tissue	O'Malley, Mole Endocrin., 4, 363, 1990	—
thyroid hormone receptor	steroid receptor super family	numerous tissues	O'Malley, Mole Endocrin., 4, 363, 1990	—
vitamin D receptor	steroid receptor super family	hematopoietic and many other cell types	O'Malley, Mole Endocrin., 4, 363, 1990	—
mineralocorti- coid receptor	steroid receptor super family	kidney, colon, salivary glands	O'Malley, Mole Endocrin., 4, 363, 1990	—
NR1-1	Kruppel zinc finger like family	CHL, placenta	Hromas, et al., J. Biol. Chem. 266, 14183, 1991	—
NR9	homeobox	hematopoietic, fetal	Deguchi and Kehrl, Blood 78, 323, 1991	—
NR24	homeobox	hematopoietic, fetal	Deguchi and Kehrl, Blood 78, 323, 1991	—

TABLE II (CONTINUED)

VRH1	homeobox	liver	Bach, et al., Nucl. Acids Res. <u>19</u> , 3553, 1991	—	—
HOX11	homeobox	liver, some T cell leukemias	Hatano, et al., Sci. <u>253</u> , 79, 1991	—	—
FL2	homeobox	cell lines	Lowney, et al., Nucl. Acids Res. <u>19</u> , 3443, 1991	—	—
rel		cell lines	Brownell, et al., Mol. Cell Biol. <u>5</u> , 2826, 1985	—	—
HSF		many cell types	Cunniff, et al., Mol. Cell Biol. <u>11</u> , 3504, 1991	—	—
MF-AR		cell lines	Won and Baumann, Mol. Cell Biol. <u>11</u> , 3001, 1991	—	—
CCG1		cell lines	Sekiguchi, et al., Mol. Cell Biol. <u>11</u> , 3317, 1991	phospho- rylated	Sekiguchi, et al., Mol. Cell. Biol., <u>11</u> , 3317, 1991
rhom-2	rhombotin	cell lines, embryonic tissue	Buetm, et al., PNAS <u>88</u> , 4367, 1991	—	—
rhom-3	rhombotin	cell lines	Buetm, et al., PNAS <u>88</u> , 4367, 1991	—	—
GATA-3		T cells	Ho, et al., EMBO J. <u>10</u> , 1187, 1991	—	—
IF-1		cell lines	Auwerx and Sassone-Corsi, Cell <u>64</u> , 983, 1991	phospho- rylated	Auwerx and Sassone-Corsi, Cell <u>64</u> , 983, 1991

TABLE III

Scoring Features of Aberrant Programming
Associated with Pathological Effects

<u>Disease</u>	<u>Cell Type</u>	<u>Representative Culture References</u>	<u>Pathological Features of Aberrant Programming</u>	<u>Pathologic Change Reference</u>
Cancer	A) Hematopoietic	A-1) Eaves, et al., J. Tiss. Cult. Meth. <u>13</u> , 55, 1991.	1) inappropriate proliferation	1-3) Kissane (ed) Anderson's Pathology C. V. Mosby St. Louis, 9th ed. 1990.
		A-2) Messner, et al., Blood <u>70</u> , 1425, 1987.	2) ability to survive in inappropriate sites in body	
		A-3) Uckin and Heerema, Leuk. Lymph. <u>2</u> , 1, 1990.	3) inappropriately invasive	
		A-4) Caligiaris-Cappio, et al., Blood <u>77</u> , 2688, 1991.		
		A-5) Hoang and McCulloch, Blood <u>66</u> , 748, 1985.		
	B) Solid Tissue	B-1) Moyer, J. Tiss. Cult. Meth. <u>8</u> , 63, 1983.	works for most primary human sarcomas and carcinomas)	
		B-2) Moyer and Poste (eds.), Colon Cancer Cells, Academic Press, San Diego, CA 1990. (Dr. Moyers' culture system		

TABLE III (CONTINUED)

Myelo- dysplasia	hematopoietic	<p>a) Firken, et al., Br. J. Haemat. <u>75</u>, 476, 1990.</p> <p>b) Aoki, et al., Amer. J. Hemat. <u>35</u>, 6, 1990.</p> <p>c) Nagler, et al., Blood <u>76</u>, 1299, 1990.</p>	<p>1) impairment of blood cell differentiation as judged by standard clinical diagnostics</p> <p>2) impaired colony formation by multi-potential progenitors</p> <p>3) immune abnormalities including (a) deficits in CD4⁺ lymphocytes and (b) decreased NK cells</p> <p>4) apoptosis</p> <p>4c) suppressed clonal expansion of myeloid progenitors from patients but not normals in presence of patient serum</p>	<p>1-3) List, et al., J. Clin. Oncol. <u>14</u>24, 1990.</p> <p>4) Clark and Lampert, Leuk. Lymph. <u>2</u>, 415, 1990.</p> <p>4c) Donohue, et al., Nature <u>326</u>, 200, 1982.</p>
	Myelo-prolif- erative Disorders	<p>a) Eaves, et al., J. Tiss. Cult. Meth. <u>13</u>, 55, 1991.</p> <p>b) Messner, et al., Blood <u>70</u>, 1425, 1987.</p> <p>c) Fauser and Messner, Blood <u>58</u>, 1224, 1981.</p>	<p>inappropriate clonal proliferation of particular blood cell lineages</p>	<p>Adamson and Fi-alkon, Br. J. Haemat. <u>38</u>, 299, 1978.</p>

TABLE III (CONTINUED)

APC/AIDS	hematopoietic	Current protocols in immunology	1) reduction in CD4 ⁺ lymphocytes and an inversion of the CD4 ⁺ to CD8 ⁺	1) Fauci, Sci. 239, 617, 1988.
		Coligan, et al. (eds.), John Wiley, Inc., N.Y. 1991	2) reduction in CD16 ⁺ CD8 ⁺ CD3 ⁺ cells	2) Mansour, et al., AIDS Res. Human Retro. 6, 1451, 1990.
			3) functional defects in lymphocytes including: (a) altered responses to certain antigens and mitogens; (b) defect in ability to under-go clonal expansion; (c) abnormalities in IL-2 receptor expression	3a) Finching and Hye, Immunol. Today 11, 256, 1990. 3a) Allouche, et al., Clin. Exp. Imm. 81, 200, 1990. 3b) Pantaleo, et al., J. Immunol. 144, 1696, 1990. 3c) Prince, et al., Clin. Exp. Immun. 67, 59, 1987. 4a) Otey, J. Int. Med. 228, 549, 1990. 4b) Zucker-Franklin and Cao, PNAS 86, 5595, 1989.
			4) functional defects in other blood cells (a) abnormal TNF production; (b) defective platelet production	

TABLE III (CONTINUED)

Atherosclerosis	smooth muscle		Shift from contractile to synthetic phenotype. Features of latter include	1) Olsson (ed) Atherosclerosis: Biology and Clinical Science, Churchill Livingstone, NY 1987.
	a) Orekhov, et al., Atherosclerosis <u>60</u> , 101, 1986.		1) proliferation	2) Jonasson, et al., J. Clin. Invest. <u>76</u> , 125, 1985.
	b) Campbell and Campbell, Vascular Smooth Muscle in Culture, Vols. I and II, CRC Press, Boca Raton, FL, 1987.		2) increased HLA-DR expression	3) Glukhova, et al., PNAS <u>85</u> , 9542, 1988.
			3) loss of muscle proteins	4) Wilcox, et al., J. Clin. Invest. <u>82</u> , 1134, 1988.
			4) growth factor production	5) Mosse, et al., Lab. Invest. <u>53</u> , 556, 1985.
			5) synthesis of extracellular matrix	6) Seifert and Hansson, J. Clin. Invest. <u>84</u> , 597, 1989.
			6) production of decay-accelerating factor	7) Betz, et al., J. Cell. Phys. <u>147</u> , 385, 1991.
			7) shift from media to intimal location	

TABLE IV

Representative Tissue Culture References
for Primary Normal Human Tissue

<u>Tissue</u>	<u>Reference</u>
Gastrointestinal (and a variety of other epithelial and mesenchymal cell types)	a) Moyer and Gendelman, J. Leuk. Biol. <u>49</u> , 499, 1991. b) Moyer, J. Tiss. Cult. Meth. <u>13</u> , 107, 1991.
bone marrow	Eaves, et al., J. Tissue Cult. Meth. <u>13</u> , 55, 1991.
hematopoietic stem cells	a) Messner, et al., Blood, <u>70</u> , 1425, 1987. b) Bernstein, et al., Blood <u>77</u> , 2316, 1991. c) Caux, et al., Blood <u>75</u> , 2292, 1990.
liver	Gomez-Lechan, et al., In Vitro Cell. Dev. Biol. <u>26</u> , 67, 1990.

TABLE V

Effect of p53 a.s. ODNs on in vitro growth of partially purified blasts from peripheral blood of patients with acute non-lymphocytic leukemia. Values represent triplicate cultures from seven separate experiments, a through g, including six different patients at either presentation or relapse. Peripheral blood leukemia blasts were isolated by Ficoll-Hypaque separation and sheep erythrocyte T-cell rosetting. Cells were plated at $5 \times 10^5/\text{ml}$ in medium as described (*). Control cultures either contained no a.s. ODNs (control), or a.s. ODN to rev (HIV). A.s. ODNs were added 24 hours after plating. In A., aliquots were removed from culture on days 5, 10 and 15 and counted for Trypan blue exclusion. In B., cells were removed on day 10 washed to remove a.s. ODN, replated at $5 \times 10^5/\text{ml}$ and counted 5 days later (day 15). nd= not done.

A.		percent viable cells of control					
a.s. ODN	day	a			b		
		5	10	15	5	10	15
Control		100	100	100	100	100	100
HIV		nd	nd	nd	54	55	75
OL(1)		88	4	1	0	0	0
A(1)		51	74	nd	0	0	0
A(3)		101	15	13	51	18	21
C(1)		60	57	41	nd	nd	nd
		c			d		
		5	10	15	5	10	15
		100	100	nd	100	100	100
		46	45	nd	100	79	89
		22	4	nd	64	21	27
		86	21	nd	64	43	29
		30	2	nd	41	24	24
		49	15	nd	55	19	17

TABLE V (CONTINUED)

B.	a.s. ODH	day	percent of control								
			e Replated			f Replated			g Replated		
			5	10	15	5	10	15	5	10	15
	Control		100	100	100	100	100	100	100	100	100
	HTV		102	85	103	83	103	92	90	97	91
	OL(1)		68	48	33	45	44	31	45	34	43
	A(1)		77	46	37	53	44	71	59	75	64
	A(3)		93	55	37	51	57	73	63	51	62
	C(1)		72	49	41	53	59	37	66	63	77

* Buick, et al., Blood 54, 95, 1979.

TABLE VI

Effect of p53 a.s. ODNs on in vitro colony formation (CFU-L) of cells removed on either day 0 or 7 of the two of the cultures described in Table V (f and g). Values represent mean \pm SD of triplicate cultures. Controls were as described in Table V. Cells were cultured according to B. Lange (*) at 1×10^5 /ml. A fraction of the cells from day 7 colonies were washed and replated at 1×10^5 /ml as described (*) in the absence of a.s. ODN. A colony was defined as >20 cells; day 7 control colonies varied from 70 to 240, day 14 colonies varied from 13 to 55. n.d. = not done.

a.s. ODN	f		g		
	replated		replated		
	day	7	14	7	14
Control		100	100	100	100
HIV		87	92	98	82
OL(1)		17	15	60	2
A(1)		28	138	79	262
A(3)		58	108	96	24
C(1)		23	8	81	4

* Lange, et al., Blood 70, 192, 1982.

TABLE VII

Effect of p53 a.s. ODN on in vitro growth of normal bone marrow. Values represent the cumulative mean \pm SD of triplicate cultures from three separate experiments. Mononuclear cells were isolated by Ficoll-Hypaque separation. Cells were plated at 2×10^6 /ml in medium as described (*) except for substituting horse for human serum. Control cultures either contained no a.s. ODN, or a.s. ODN to rev (HIV). A.s. ODNs were added 24 hours after plating. Aliquots were removed from culture on days 5 and 10, and counted for Trypan blue exclusion.

a.s. ODN	Viable cells $\times 10^5$	
	day 5	10
Control	12.7 \pm 3.3	13.1 \pm 2.5
HIV	11.8 \pm 2.6	11.5 \pm 2.2
OL(1)	12.1 \pm 2.6	12.0 \pm 1.8
A(1)	11.9 \pm 2.1	12.2 \pm 1.5
A(3)	12.1 \pm 2.7	14.5 \pm 1.4
C(1)	9.7 \pm 2.0	10.9 \pm 0.5

* Bayever, et al., Exp. Cell Rev. 179, 168, 1988.

TABLE VIII

Effect of p53 a.s. ODNs on in vitro colony formation of hematopoietic progenitors removed on day 7 from three of the normal bone marrow cultures described in Table VI. Values represent the cumulative mean \pm SD of triplicate cultures. Controls were as described in Table V. Cells were cultured as described (*), except they were plated at $1 \times 10^5/\text{ml}$. A fraction of the cells from day 7 colonies were washed and replated at $5 \times 10^4/\text{ml}$ for the CFU-Mix and BFU-E, or $1 \times 10^5/\text{ml}$ for the CFU-GM as described (*). A colony was defined as >20 cells. All colonies were cultured in the absence of a.s. ODNs.

a.s. ODN	CFU-Mix	BFU-E	CFU-GM
Control	3.9 ± 4.5	4.4 ± 7.2	237.6 ± 100.1
HIV	1.1 ± 0.9	1.0 ± 1.0	329.1 ± 161.9
OL(1)	1.8 ± 1.8	15.8 ± 1.8	278.9 ± 117.9
A(1)	9.5 ± 6.7	11.6 ± 7.8	330.3 ± 123.8
A(3)	1.0 ± 1.0	1.3 ± 1.8	261.3 ± 90.2
C(1)	3.4 ± 4.1	1.0 ± 1.9	254.5 ± 94.9

* Messner, et al., Blood 70, 1425, 1987.
Caux, et al., Blood 75, 2292, 1990.

TABLE IX

Method for non-human primate peripheral blood T-cell studies:

1. Heparinized blood was diluted by one third with HBSS, layered over Ficoll-Hypaque and centrifuged at 1600 r.p.m., for 40 minutes at 20°C.
2. Interface mononuclear cells were recovered and washed twice with HBSS, resuspended in RPMI 1640 with 10% FCS to $1 \times 10^6/\text{ml}$ in the presence of PHA ($10\mu\text{g}/\text{ml}$).
3. Cells were incubated at 37°C in 5% CO₂ for 72 to 96 hours.
4. Cells were harvested, washed and replated at $5 \times 10^5/\text{ml}$ in medium consisting of RPMI 1640 with 10% FCS and 10% IL-2.
5. After a 24 hour incubation the a.s. ODN was added to the culture at a $10\mu\text{M}$ concentration.
6. At 2 to 3 day intervals an aliquot was removed and counted for Trypan blue exclusion.

TABLE IX (cont.)

BMC039 - PHA-primed human T-cells

8/14/91

KMH

PHA stimulated → Day 4 wash + place in IL-2 =
 "Day 0", "Day 1" add 10 μ M oligo

	<u>Media</u>	<u>A(1)</u>	<u>Oh(1)</u>	<u>A(3)</u>	<u>C(1)</u>	<u>HIV-2</u>
<u>Day 0</u>	2x10 ⁵ /ml	2x10 ⁵ /ml	2x10 ⁵ /ml	2x10 ⁵ /ml	2x10 ⁵ /ml	2x10 ⁵ /ml
<u>Day 2</u>	8x10 ⁵	3.6	5	4.2	4.2	6.8
	8.2	4.4	5.2	5	5	7.4
	<u>7.4</u>	<u>3.8</u>	<u>4</u>	<u>4</u>	<u>5.2</u>	<u>8.6</u>
	7.9x10 ⁵	3.9x10 ⁵	4.7x10 ⁵	4.4x10 ⁵	4.8x10 ⁵	7.6x10 ⁵
<u>Day 4</u>	11.2x10 ⁵	7.2	5.6	4	9.2	10.6
	11.4	6.6	8	6	8.6	10.4
	<u>10.6</u>	<u>8</u>	<u>6.2</u>	<u>7.2</u>	<u>7.8</u>	<u>10</u>
	11.1x10 ⁵	7.3x10 ⁵	6.6x10 ⁵	5.7x10 ⁵	8.5x10 ⁵	10.3x10 ⁵
<u>Day 7</u>	18.2x10 ⁵	7	8.8	13	9.2	15.4
	19.6	7.4	6.6	10.4	10.8	14.2
	<u>18.8</u>	<u>8.2</u>	<u>9.8</u>	<u>11.2</u>	<u>11.6</u>	<u>14.6</u>
	18.9x10 ⁵	7.5x10 ⁵	8.4x10 ⁵	11.5x10 ⁵	10.5x10 ⁵	14.7x10 ⁵

On "Day 4" cells were removed, washed free of oligo and replated at 2x10⁵/ml.

Replated cells → single cells

→ * (Day 4 = 2x10⁵/each)

	<u>Media</u>	<u>A(1)</u>	<u>Oh(1)</u>	<u>A(3)</u>	<u>C(1)</u>	<u>HIV-2</u>
<u>Day 7</u>	6.3x10 ⁵	6.6	6.5	6.1	6.5	6.1
<u>Day 9</u>	7.1x10 ⁵	6.8	6.8	6.9	6.9	6.7

TABLE IX (CONTINUED)

BMC028 - 2 samples of monkey PB

8/14/91

KMH

PHA prime → onto IL-2, then oligo

	<u>Media</u>	<u>A(1)</u>	<u>Oh(1)</u>	<u>A(3)</u>	<u>C(1)</u>	<u>HIV-2</u>
<u>Day 0</u>	2x10 ⁵ /ml	2x10 ⁵ /ml	2x10 ⁵ /ml	2x10 ⁵ /ml	2x10 ⁵ /ml	2x10 ⁵ /ml
<u>Day 1</u>	10μM oligo	10μM oligo	10μM oligo	10μM oligo	10μM oligo	10μM oligo
<u>Day 4</u>						
<u>Primate A</u>						
	1.0x10 ⁵	0.6	0.47	0.33	0.53	1.2
	<u>1.13</u>	<u>0.47</u>	<u>0.47</u>	<u>0.27</u>	<u>0.4</u>	<u>1.0</u>
	1.07x10 ⁵	0.53x10 ⁵	0.47x10 ⁵	0.3x10 ⁵	0.47x10 ⁵	1.1x10 ⁵
<u>Primate B</u>						
	1.93x10 ⁵	1.67	0.67	0.73	0.53	1.6x10 ⁵
<u>Day 6</u>						
<u>Primate A</u>						
	2.0x10 ⁵	1.4	1.07	1.33	1.4	3.2
	<u>2.93</u>	<u>1.2</u>	<u>1.33</u>	<u>1.07</u>	<u>1.2</u>	<u>2.67</u>
	2.47x10 ⁵	1.33x10 ⁵	1.2x10 ⁵	1.2x10 ⁵	1.33x10 ⁵	2.93x10 ⁵
<u>Primate B</u>						
	2.2x10 ⁵	1.2x10 ⁵	0.7x10 ⁵	1x10 ⁵	0.8x10 ⁵	2.3x10 ⁵
<u>Day 8 bacteria in A</u>						
<u>Primate B</u>						
	2.9x10 ⁵	1x10 ⁵	0.4x10 ⁵	0.7x10 ⁵	1.2x10 ⁵	2.4x10 ⁵
<u>Day 10 bacteria emerging in B</u>						

SUBSTITUTE SHEET

* * *

While the present invention has been described in conjunction with a preferred embodiment and specific examples, the description is not meant to limit it. One of ordinary skill, with the aid of the present disclosure, may be able to effect various changes, substitutions of equivalents and other alterations to the methods and compositions set forth. Therefore, the protection granted by Letters Patent should not be limited except by the language of the claims as set forth below.

"SEQUENCE LISTING"

(1) GENERAL INFORMATION

(i) APPLICANT: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA

(ii) TITLE OF INVENTION: Methods and Compositions for Therapeutic Cellular Reprogramming

(iii) NUMBER OF SEQUENCES: (5)

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: John P. Floyd, Esq.
(B) STREET: 200 Roger Webster
(C) CITY: Williamsburg
(D) STATE: Virginia
(E) COUNTRY: U.S.A.
(F) ZIP: 23187-3609

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: floppy disk, 5.25 inch, 360Kb Storage
(B) COMPUTER: IBM-compatible, 486/33
(C) OPERATING SYSTEM: MS-DOS 5.0
(D) SOFTWARE: WordPerfect 5.1

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: not available
(B) FILING DATE: not available
(C) CLASSIFICATION: not available

(vii) PRIOR APPLICATION DATA: none

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: FLOYD, John P.

(B) REGISTRATION NUMBER: 19528

(C) REFERENCE/DOCKET NUMBER: 63032PCT

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (804) 220-0930

(B) TELEFAX: (804) 220-0930

(2) INFORMATION FOR SEQ ID NO:1

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 nucleotide bases

(B) TYPE: nucleic

(C) STRANDEDNESS: single stranded

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other Nucleic Acid

(A) DESCRIPTION: oligonucleotide

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(xi) SEQUENCE DESCRIPTION:SEQ ID NO:1:

TCTCTCCGCT TCTTCCTGCC

20

(2) INFORMATION FOR SEQ ID NO:2

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 nucleotide bases

(B) TYPE: nucleic

(C) STRANDEDNESS: single stranded

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other Nucleic Acid

(A) DESCRIPTION: oligonucleotide

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(xi) SEQUENCE DESCRIPTION:SEQ ID NO:2:

ATCTGACTGC GGCTCCTCCA

20

(2) INFORMATION FOR SEQ ID NO:3

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 nucleotide bases

(B) TYPE: nucleic

(C) STRANDEDNESS: single stranded

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other Nucleic Acid
(A) DESCRIPTION: oligonucleotide

(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: yes

(xi) SEQUENCE DESCRIPTION:SEQ ID NO:3:
GACAGCATCA AATCATCCAT.

20

(2) INFORMATION FOR SEQ ID NO:4

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 nucleotide bases
(B) TYPE: nucleic
(C) STRANDEDNESS: single stranded
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other Nucleic Acid
(A) DESCRIPTION: oligonucleotide

(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: yes

(xi) SEQUENCE DESCRIPTION:SEQ ID NO:4:
CCCTGCTCCC CCCTGGCTCC

20

(2) INFORMATION FOR SEQ ID NO:5

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 nucleotide bases
(B) TYPE: nucleic
(C) STRANDEDNESS: single stranded
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other Nucleic Acid
(A) DESCRIPTION: oligonucleotide

(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: yes

(xi) SEQUENCE DESCRIPTION:SEQ ID NO:5:
AGTCTTGAGC ACATGGGAGG

20

WHAT IS CLAIMED IS:

1. A method for treating an individual having an Aberrant Programming disease comprising administering to said individual an effective amount of a composition selected from the group consisting of an expression vector, a double stranded oligodeoxynucleotide, and an antisense oligodeoxynucleotide; said composition capable of regulating expression of a transcriptional regulator, said transcriptional regulator being expressed by the Aberrant Programming cells and further characterized by exhibiting a therapeutically useful change in said cell behavior in the Reprogramming Test.

2. The method of claim 1 wherein said Aberrant Programming disease is AIDS and said transcriptional regulator is not encoded by HIV.

3. The method of claim 1 wherein said Aberrant Programming disease is cancer and said transcriptional regulator is a Traitor Gene.

4. The method of claim 1 wherein said Aberrant Programming disease is cancer and said transcriptional regulator excludes oncogenes.

5. A method for treating an individual having a clinical disorder comprising administering to said individual an effective amount of a composition selected from the group consisting of a double stranded oligodeoxynucleotide and an antisense oligodeoxynucleotide; said composition capable of regulating expression of a transcriptional regulator, said transcriptional regulator being expressed by

therapeutically relevant cells and further characterized by exhibiting a therapeutically useful change in said cell behavior in the Reprogramming Test.

6. A method for treating therapeutically relevant cells from an individual having a clinical disorder prior to transplantation of the cells back into the individual comprising the steps of:

- a) obtaining therapeutically relevant cells for the individual and
- b) exposing the therapeutically relevant cells to a reprogramming amount of an oligodeoxynucleotide having a sequence complementary to a sequence of RNA transcribed from a transcriptional regulator regulated gene or double stranded oligodeoxynucleotide ligand of a transcriptional regulator present in the transcriptional regulator cells.

7. The method of claim 6 wherein the cells are taken from prenatal tissue.

8. The method of claim 6 wherein the cells are taken from a different donor than the individual under treatment.

9. A method for diagnosing or staging an Aberrant Programming disease comprising identifying the relevant subset of transcriptional regulators expressed by Aberrant Programming cells from an Aberrant Programming patient.

10. A method for selecting the most efficacious treatment regimen for an Aberrant Programming disease comprising identifying the relevant subset of

transcriptional regulators expressed by Aberrant Programming cells from an Aberrant Programming patient.

11. A method for selecting the most efficacious treatment regimen for an Aberrant Programming disease comprising removing Aberrant Programming cells from an Aberrant Programming patient and culturing with an antisense oligodeoxynucleotide to a transcriptional regulator or a double stranded oligodeoxynucleotide to the DNA binding domain of the transcriptional regulator to determine optimal treatment.

12. A method for the selection of a target for the treatment of an Aberrant Programming disease comprising (i) determining the subset of transcriptional regulators and their direct modifiers expressed by the aberrantly programmed tissue, the corresponding normal tissue, or the constitutively self-renewing normal tissue or, alternatively, making a similar determination for any other normal tissue that is to be therapeutically manipulated in accordance with this invention; (ii) adding or subtracting expression of transcriptional regulator(s), or their direct modifiers, from cells to be therapeutically reprogrammed and the appropriate control tissue; (iii) scoring effect on cellular programming and selecting potential therapeutic agents; (iv) testing effect of addition or subtraction of the function of particular transcriptional regulators, using the agents selected, (in an animal model system if the therapeutic agents are for systemic use), and (v) reducing or eliminating any undesirable side effects that might be produced by the potential therapeutic

agents. This embodiment is described in detail hereinafter.

13. An oligodeoxynucleotide, having between about 10 and about 30 bases, and containing a sequence selected from the group consisting of:

5'-ATCTGACTGC GGCTCCTCCA-3'

5'-GACAGCATCA AATCATCCAT-3'

5'-CCCTGCTCCC CCCTGGCTCC-3'

5'-AGTCTTGAGC ACATGGGAGG-3'.

14. The oligodeoxynucleotide of claim 13 wherein the melting point is equal to or greater than 40°C.

15. The method of claims 1, 5, 6, 7, 8, 9, 10, 11, and 12 where the effective dose is between about 1 nanomolar and about 5 micromolar in extra-cellular fluid.

DNA SYNTHESIS-THYMIDINE INCORPORATION
EFFECTS OF ANTI-SENSE OLIGOS ON GI CELLS




FIG. 1

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US92/07133

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : A61K 48/00
US CL : 514/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/44

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
none

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
APS, DIALOG: Search terms - combinatorial regulation, transcriptional regulators, traitor genes, aberrant programming disease, p53

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Science, volume 250, issued 16 November 1990, BIELINSKA ET AL. , "Regulation of Gene Expression with Double Standard Phosphorothioate Oligonucleotides", pages 997-1000, see the entire document.	1-5
Y	Gene, volume 89, issued 1990, W ET AL. , "Inhibition of in vitro description by specific double stranded oligodexynucleotides", pages 203-209, see the entire article.	9, 10, 12
P	US, A, 5,087,617 (SMITH) 11 February 1992, see the entire document.	1-15
Y	Journal of Experimental Medicine, volume 164, issued September 1986, SMITH ET AL. , "Expression of the p53 oncogene in acute myeloblastic leukemia", pages 751-761, see the entire article.	5
Y	US, A, 4,690,915 (ROSENBERG) 01 September 1987, see the entire document.	6-8, 11

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be part of particular relevance	X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	Z	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

22 OCTOBER 1992

Date of mailing of the international search report

23 NOV 1992

Name and mailing address of the ISA/
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. NOT APPLICABLE

Authorized officer

SUZANNE ZISKA

Telephone No. (703) 308-3964

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US92/07133

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EMBO Journal, volume 3, no. 13, issued 1984, MATLASHEWSKI ET AL., "Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene", pages 3257-3262, see the entire article.	13-15